Catalyst Biosciences Announces Multiple Presentations at the Scientific and Standardization Committee Meeting of the Internat...
July 12 2018 - 8:00AM
Conference call and webcast to be held Wednesday,
July 18, 2018 at 8:30 a.m. EDT
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced the presentation of
two posters at the 64th Annual Scientific and Standardization
Committee (SSC) Meeting of the International Society on Thrombosis
and Haemostasis (ISTH) being held in Dublin on July 18-21, 2018.
The posters, presented by Dr. Howard Levy, chief
medical officer of Catalyst, entitled: “Phase 2 Trial of
Subcutaneously Administered Novel FVIIa Variant, Marzeptacog alfa
(activated), in Hemophilia A or B with Inhibitors:
Pharmacokinetics, Pharmacodynamics, Safety and Efficacy” and “Phase
1/2 Trial of Single and Multiple Dose Subcutaneously Administered
Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Safety,”
will discuss the current clinical data from Catalyst’s hemophilia
programs.
Dr. Levy said, “We look forward to sharing
interim data from our Factor VIIa program demonstrating the
efficacy of subcutaneously (SQ) administered marzeptacog alfa
(activated) for the treatment of hemophilia A or B with inhibitors.
We will also provide an update on our SQ Factor IX CB 2679d program
for the treatment of hemophilia B.”
Poster presentations |
|
|
Presentation
Title: |
Phase 2 Trial of Subcutaneously Administered Novel FVIIa
Variant, Marzeptacog alfa (activated), in Hemophilia A or B with
Inhibitors: Pharmacokinetics, Pharmacodynamics, Safety and
Efficacy |
|
Presenter: |
Howard
Levy, M.B.B.Ch., Ph.D., M.M.M. |
|
Abstract Number: |
PB196 |
|
Session: |
Poster
Session #1 |
|
Date/Time: |
Wednesday,
July 18, 2018 from 5:00-6:30 p.m. IST |
|
|
|
|
Presentation
Title: |
Phase 1/2 Trial of Single and Multiple Dose Subcutaneously
Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and
Safety |
|
Presenter: |
Howard
Levy, M.B.B.Ch., Ph.D., M.M.M. |
|
Abstract
Number: |
PB159 |
|
Session: |
Poster
Session #1 |
|
Date/Time: |
Wednesday,
July 18, 2018 from 5:00-6:30 p.m. IST |
A copy of the presentation materials can be
accessed on the Events and Presentations section of the Catalyst
website once the presentations conclude.
Conference Call DetailsThe
management team will host a conference call for investors on
Wednesday July 18, 2018, at 8:30 a.m. EDT to discuss the Factor
VIIa and Factor IX clinical data. Conference call, webcast and
post-conference call replay details are as follows:
Domestic: +1.877.425.9470International:
+1.201.389.0878Conference ID: 13681615Webcast:
http://public.viavid.com/index.php?id=130521
A replay will be available two hours after
completion of the call through August 1, 2018: Domestic:
+1.844.512.2921International: +1.412.317.6671Replay ID:
13681615
About CatalystCatalyst is a
clinical-stage biopharmaceutical company developing novel medicines
to address hematology indications. Catalyst is focused on the field
of hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statement of historical fact, included in
this press release regarding our strategy, the efficacy of
subcutaneously administered marzeptacog alfa (activated), potential
uses and benefits of CB 2679d and marzeptacog alfa (activated), and
development plans for these product candidates are forward-looking
statements. Actual results or events could differ materially from
the plans, intentions, expectations and projections disclosed in
the forward-looking statements as a result of various important
factors, including, but not limited to, the risk that trials and
studies may be delayed and may not have satisfactory outcomes, that
ongoing or future trials will not replicate the results from
earlier human trials or from prior animal studies, that potential
adverse effects may arise from the testing or use of the Company’s
products, including the generation of antibodies, the risk that
costs required to develop or manufacture the Company’s products
will be higher than anticipated, competition and other factors that
affect our ability to establish collaborations on commercially
reasonable terms and other risks described in the “Risk Factors”
section of the Company’s Annual Report on Form 10-K for the year
ended December 31, 2017, filed with the Securities and Exchange
Commission on March 19, 2018, along with our other filings with the
Securities and Exchange Commission. The Company does not assume any
obligation to update any forward-looking statements, except as
required by law.
Contacts
Investors:Fletcher Payne, CFOCatalyst
Biosciences, Inc.+1.650.871.0761investors@catbio.com
Media:Josephine Belluardo, Ph.D.LifeSci Public
Relations+1.646.751.4361jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024